AtheroGenics Gets Good News From Phase III Trial for Diabetes

AtheroGenics received positive data from its ANDES Phase III clinical trial of AGI-1067 for the treatment of Type 2 diabetes.

Results from the multinational, double-blind, placebo-controlled, dose-finding study showed both doses (75 mg and 150 mg) of the drug met the primary efficacy endpoint of the reduction in glycosylated hemoglobin compared with placebo at the end of the study’s six-month dosing regimen, the company said.

The study involved 999 patients and took place at 150 clinical sites in the U.S., South Africa, India and Eastern Europe.